Since altered lipoprotein metabolism was noted in ALS, our study findings provide evidence for the first time that ApoA1 may be a potential novel therapeutic agent for protection of the endothelium in this devastating disease. Here, APOA1 is linked to amyotrophic lateral sclerosis.